Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
HBV DNA level at 24 weeks is the best predictor of virological response to adefovir add-on therapy in patients with lamivudine resistance.
Shin JW, Jung SW, Park BR, Kim CJ, Eum JB, Kim BG, Du Jeong I, Bang SJ, Park NH.
Antivir Ther. 2012;17(2):387-94. doi: 10.3851/IMP1945. Epub 2011 Nov 2.
Related citations
Lamivudine-resistant HBV infection in HIV-positive patients receiving antiretroviral therapy in a public routine clinic in Cameroon.
Kouanfack C, Aghokeng AF, Mondain AM, Bourgeois A, Kenfack A, Mpoudi-Ngolé E, Ducos J, Delaporte E, Laurent C.
Antivir Ther. 2012;17(2):321-6. doi: 10.3851/IMP1911. Epub 2011 Sep 23.
HIV and hepatitis virus resistance to antivirals: review of data from the XIX International HIV and Hepatitis Virus Drug Resistance Workshop and curative strategies.
Mascolini M, Mellors JW, Richman DD, Boucher CA, Larder BA.
Antivir Ther. 2011;16(2):263-86.
Transmitted raltegravir resistance in an HIV-1 CRF_AG-infected patient.
Boyd SD, Maldarelli F, Sereti I, Ouedraogo GL, Rehm CA, Boltz V, Shoemaker D, Pau AK.
Antivir Ther. 2011;16(2):257-61.
Transmission of integrase strand-transfer inhibitor multidrug-resistant HIV-1: case report and response to raltegravir-containing antiretroviral therapy.
Young B, Fransen S, Greenberg KS, Thomas A, Martens S, St Clair M, Petropoulos CJ, Ha B.
Antivir Ther. 2011;16(2):253-6.
Transmitted resistance to HIV integrase strand-transfer inhibitors: right on schedule.
Hurt CB.
Antivir Ther. 2011;16(2):137-40.
Multi-nucleoside reverse transcriptase inhibitor resistant HIV type-1 in a patient from Sierra Leone failing stavudine, lamivudine and nevirapine.
Hamers RL, Wensing AM, Back NK, Arcilla MS, Frissen JP.
Antivir Ther. 2011;16(1):115-8.
Minor drug-resistant HIV type-1 variants in breast milk and plasma of HIV type-1-infected Ugandan women after nevirapine single-dose prophylaxis.
Pilger D, Hauser A, Kuecherer C, Mugenyi K, Kabasinguzi R, Somogyi S, Harms G, Kunz A.
Antivir Ther. 2011;16(1):109-13.
Virological characterization of patients failing darunavir/ritonavir or lopinavir/ritonavir treatment in the ARTEMIS study: 96-week analysis.
Lathouwers E, De Meyer S, Dierynck I, Van de Casteele T, Lavreys L, de Béthune MP, Picchio G.
Antivir Ther. 2011;16(1):99-108.
Comparison of multiplex restriction fragment mass polymorphism and sequencing analyses for detecting entecavir resistance in chronic hepatitis B.
Han KH, Hong SP, Choi SH, Shin SK, Cho SW, Ahn SH, Hahn JS, Kim SO.
Antivir Ther. 2011;16(1):77-87.
Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
Pulido F, Arribas JR, Hill A, Van Delft Y, Moecklinghoff C.
Antivir Ther. 2011;16(1):59-65.
HBV core region variability: effect of antiviral treatments on main epitopic regions.
Homs M, Jardi R, Buti M, Schaper M, Tabernero D, Fernandez-Fernandez P, Quer J, Esteban R, Rodriguez-Frias F.
Antivir Ther. 2011;16(1):37-49.
HIV type-1 drug resistance in treatment-naive patients monitored using minority species assays: a systematic review and meta-analysis.
Buckton AJ, Harris RJ, Pillay D, Cane PA.
Antivir Ther. 2011;16(1):9-16. Review.
High prevalence of antiretroviral drug resistance among HIV-1-untreated patients in Guinea-Conakry and in Niger.
Charpentier C, Bellecave P, Cisse M, Mamadou S, Diakite M, Peytavin G, Tchiombiano S, Teisseire P, Pizarro L, Storto A, Brun-Vézinet F, Katlama C, Calvez V, Marcelin AG, Masquelier B, Descamps D.
Antivir Ther. 2011;16(3):429-33.
Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients.
Treviño A, de Mendoza C, Parra P, Rodríguez C, Madejón A, Plaza Z, del Romero J, Poveda E, Soriano V.
Antivir Ther. 2011;16(3):413-6.
Baseline CD4(+) T-cell counts and weighted background susceptibility scores strongly predict response to maraviroc regimens in treatment-experienced patients.
Schapiro JM, Boucher CA, Kuritzkes DR, van de Vijver DA, Llibre JM, Lewis M, Simpson P, Delogne C, McFadyen L, Chapman D, Perros M, Valdez H, van der Ryst E, Westby M.
Antivir Ther. 2011;16(3):395-404.
Predicting antiretroviral drug resistance from the latest or the cumulative genotype.
Garcia F, Alvarez M, Fox Z, Garcia-Diaz A, Guillot V, Johnson M, Chueca N, Phillips A, Hernández-Quero J, Geretti AM.
Antivir Ther. 2011;16(3):373-82.
Pleconaril-resistant chronic parechovirus-associated enteropathy in agammaglobulinaemia.
van de Ven AA, Douma JW, Rademaker C, van Loon AM, Wensing AM, Boelens JJ, Sanders EA, van Montfrans JM.
Antivir Ther. 2011;16(4):611-4.
Neuraminidase of 2007-2008 influenza A(H1N1) viruses shows increased affinity for sialic acids due to the D344N substitution.
Rameix-Welti MA, Munier S, Le Gal S, Cuvelier F, Agou F, Enouf V, Naffakh N, van der Werf S.
Antivir Ther. 2011;16(4):597-603.
HBV primary drug resistance in newly diagnosed HIV-HBV-coinfected individuals in Spain.
Tuma P, Pineda JA, Labarga P, Vidal F, Rodriguez C, Poveda E, Santos J, Gonzalez-García J, Sobrino P, Tural C, Soriano V; CoRIS Study Group.
Antivir Ther. 2011;16(4):585-9.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on